Results 51 to 60 of about 368,835 (244)

Hemangiosarcoma of the third eyelid in a horse [PDF]

open access: yes, 2009
A 12-year-old Belgian Warmblood mare was referred to the equine clinic of the Faculty of Veterinary Medicine (Ghent University) for a mass on the third eyelid of the right eye. The horse had been having a recurrent red-tinged ocular discharge for several
Chiers, Koen   +4 more
core  

p16INK4A expression is frequently increased in periorbital and ocular squamous lesions [PDF]

open access: yes, 2015
Backgroundp16 expression is a well established biomarker of cervical dysplasia and carcinoma arising from high risk human papilloma virus infection. Increased p16 expression is also seen in squamous neoplasms arising at other sites, including head, neck,
Bobby S. Korn   +7 more
core   +2 more sources

Metronidazole‐Loaded Cyclodextrin Nanogels for Antibacterial Therapy and Microbiota Regulation in Periodontitis

open access: yesAdvanced Healthcare Materials, EarlyView.
A methacrylamide β‐cyclodextrin‐based nanogel (MACD nGel) is developed to load the antimicrobial drug Metronidazole (MNZ) for topical delivery for the treatment of periodontitis. It is demonstrated that cyclodextrin nanogel (nGel) loaded with metronidazole provides an efficient drug delivery route but also has potential clinical applications and offers
Yanjing Ji   +8 more
wiley   +1 more source

CD147/Basigin: From Integrative Molecular Hub to Translational Therapeutic Target

open access: yesAdvanced Science, EarlyView.
This review conceptualizes CD147 as a fundamental “Energy‐Structure Coupler,” physically bridging metabolic flux (via MCTs) with morphogenetic plasticity (via integrins/MMPs) to drive cancer, infection, and autoimmunity. Addressing the “specificity paradox” that limits current translation, the authors chart a strategic roadmap—spanning logic‐gated ...
Xiang‐Min Yang   +2 more
wiley   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

open access: yesBMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen   +7 more
wiley   +1 more source

Severe Case of Peripheral Leukocytosis Initially Diagnosed as Myelodysplastic Syndrome/Myeloproliferative Neoplasm, Unclassifiable, but Possibly Prefibrotic Primary Myelofibrosis [PDF]

open access: yes, 2014
Leukocytosis is occasionally seen in patients with presumptive but undiagnosed myeloproliferative disorders (MPD). A 74-year-old woman was admitted to our hospital for tarry stools, anemia, and marked peripheral leukocytosis of 1.4×105/μL ...
Hiramatsu, Yasushi   +8 more
core   +1 more source

Clinical characteristics, treatment response, and survival outcomes in melanoma patients with cavity carcinomatosis: A retrospective analysis

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Cavity carcinomatosis, a late manifestation of cancer, fuels tumor formation throughout a large area, most commonly the peritoneal and pleural cavities. The condition also can lead to resistance to otherwise effective treatment strategies.
Zhongqiao Lin   +6 more
wiley   +1 more source

The efficiency of radiowave technology in out-patient eye surgery

open access: yesРоссийский офтальмологический журнал, 2019
Purpose: to analyze the technique of outpatient operations using radiowave surgery.Material and methods. The clinical group of 691 patients (691 eyes; 315 men and 376 women aged 39.7 ± 4.2 years), with various pathologies of the eye and adnexa, in ...
I. A. Filatova, Yu. P. Kondratyeva
doaj   +1 more source

HIV and HPV infections and ocular surface squamous neoplasia: systematic review and meta-analysis. [PDF]

open access: yes, 2013
BACKGROUND: The frequency of ocular surface squamous neoplasias (OSSNs) has been increasing in populations with a high prevalence of infection with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) and infection with human ...
A Timm   +62 more
core   +4 more sources

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy